Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.
EP: 1.Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
EP: 2.Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
EP: 3.Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
EP: 4.Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
EP: 5.Treating Patients with High-Risk NDMM
EP: 6.Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
EP: 7.Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
EP: 8.Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
EP: 9.Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
EP: 10.Maintenance Therapy in Transplant-Ineligible NDMM
EP: 11.Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP: 12.Bispecific Antibodies in the Treatment of R/R MM
EP: 13.CAR-T Therapy in R/R MM Treatment
Now Viewing
EP: 14.Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
EP: 15.Sequencing Therapies in Patients with R/R MM
EP: 16.Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
EP: 17.Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
